- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Drugs with High Efficacy against Tumor Angiogenesis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 13, Pages 6934
Publisher
MDPI AG
Online
2022-06-23
DOI
10.3390/ijms23136934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Extracellular HSPs: The Potential Target for Human Disease Therapy
- (2022) Dong-Yi Li et al. MOLECULES
- The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
- (2021) Sophia Daum et al. Frontiers in Cell and Developmental Biology
- Angiopoietin inhibitors: A review on targeting tumor angiogenesis
- (2021) Digna Parmar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
- (2021) Martina Spisarová et al. Expert Review of Anticancer Therapy
- Effect of Exogenous Melatonin on the Development of Mice Ovarian Follicles and Follicular Angiogenesis
- (2021) Jingli Tao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 3D tumor angiogenesis models: recent advances and challenges
- (2021) Sharath M. Bhat et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination
- (2021) Camille L. Duran et al. Cancers
- Weibel Palade Bodies: Unique Secretory Organelles of Endothelial Cells that Control Blood Vessel Homeostasis
- (2021) Johannes Naß et al. Frontiers in Cell and Developmental Biology
- HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis
- (2020) Yanling Niu et al. CANCER RESEARCH
- Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan
- (2020) Teruo Inamoto et al. Expert Review of Anticancer Therapy
- HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer
- (2020) Ryoji Eguchi et al. ONCOLOGY REPORTS
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
- (2020) Seon-Hyeong Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
- (2020) Kayoko Hosaka et al. Nature Communications
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2020) Arshad M. Khanani et al. JAMA Ophthalmology
- Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells
- (2020) Bogdana Kovalchuk et al. CLINICAL & EXPERIMENTAL METASTASIS
- The role of microenvironment in tumor angiogenesis
- (2020) Xianjie Jiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
- (2020) Florian Heil et al. Translational Oncology
- Extended (≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials
- (2019) Rahul N. Khurana et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
- (2019) Tiziana Annese et al. Cancers
- Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
- (2019) Jayashree Sahni et al. OPHTHALMOLOGY
- AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation
- (2019) Feng Li et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model
- (2019) Thomas Mueller et al. MOLECULES
- 74TiPPhase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
- (2019) K Yamazaki et al. ANNALS OF ONCOLOGY
- AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo
- (2019) Peng-Chao Zhang et al. BIOCHEMICAL PHARMACOLOGY
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Antiangiogenic compounds: well-established drugs versus emerging natural molecules
- (2018) Andreia Ribeiro et al. CANCER LETTERS
- Vascular endothelial growth factor signaling in development and disease
- (2018) Sinem Karaman et al. DEVELOPMENT
- EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer
- (2018) Shaoxin Cai et al. EXPERIMENTAL CELL RESEARCH
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Tumor angiogenesis and anti‑angiogenic gene therapy for cancer (Review)
- (2018) Tinglu Li et al. Oncology Letters
- Tumor Angiogenesis: A Key Target for Cancer Therapy
- (2018) Dieter Marmé Oncology Research and Treatment
- A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
- (2018) Nicolas Isambert et al. JOURNAL OF CLINICAL ONCOLOGY
- PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
- (2018) Tianrun Liu et al. Nature Communications
- COPD-Type lung inflammation promotes K-ras mutant lung cancer through epithelial HIF-1α mediated tumor angiogenesis and proliferation
- (2018) Maria Miguelina De la Garza et al. Oncotarget
- Tumor microenvironment: Interactions and therapy
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Prognostic role of HPV infection in esophageal squamous cell carcinoma
- (2018) Laura Bognár et al. Infectious Agents and Cancer
- Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
- (2017) Keehoon Jung et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer
- (2017) Keehoon Jung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
- (2017) Biagio Ricciuti et al. SEMINARS IN CANCER BIOLOGY
- Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
- (2017) M. Wroblewski et al. Nature Communications
- Erratum: Acute myeloid leukemia targets for bispecific antibodies
- (2017) S S Hoseini et al. Blood Cancer Journal
- Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors
- (2017) Nadine Mahfouz et al. PLoS One
- Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects
- (2016) Dong Li et al. CANCER LETTERS
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- Angiocrine functions of organ-specific endothelial cells
- (2016) Shahin Rafii et al. NATURE
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
- (2016) Caroline Wigerup et al. PHARMACOLOGY & THERAPEUTICS
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
- (2016) N. N. Rahbari et al. Science Translational Medicine
- The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance
- (2016) Lejla Alidzanovic et al. Oncotarget
- Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
- (2016) Yijia Qin et al. Thoracic Cancer
- Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis
- (2015) Srimathi Srinivasan et al. ANGIOGENESIS
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Anti-cancer activity of withaferin A in B-cell lymphoma
- (2015) MK McKenna et al. CANCER BIOLOGY & THERAPY
- PI3K–mTORC2 but not PI3K–mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma
- (2015) Sofie Mohlin et al. CANCER RESEARCH
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells
- (2015) Shigeo Saito et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
- (2015) Anna S. Berghoff et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
- (2015) Enrica Borsi et al. Translational Research
- Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies
- (2015) Agnieszka Zimna et al. Biomed Research International
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
- (2014) M. Chiron et al. MOLECULAR CANCER THERAPEUTICS
- Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
- (2014) A. S. Berghoff et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- (2013) M Peeters et al. BRITISH JOURNAL OF CANCER
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Angiopoietin signaling in the vasculature
- (2013) Lauri Eklund et al. EXPERIMENTAL CELL RESEARCH
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- VEGFA and tumour angiogenesis
- (2013) L. Claesson-Welsh et al. JOURNAL OF INTERNAL MEDICINE
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
- (2013) Yasushi Soda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis
- (2013) Young-Sool Hah et al. ARTHRITIS RESEARCH & THERAPY
- The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway
- (2013) G. Thurston et al. Cold Spring Harbor Perspectives in Medicine
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors
- (2012) Yang-Fei Xiang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)
- (2012) Christopher Daly et al. CANCER RESEARCH
- Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
- (2012) Janice A. Nagy et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Heat-Shock Protein Axis Regulates VEGFR2 Proteolysis, Blood Vessel Development and Repair
- (2012) Alexander F. Bruns et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis
- (2011) M N Khan et al. BRITISH JOURNAL OF CANCER
- Hypoxia, stem cells and bone tumor
- (2011) Wen Zeng et al. CANCER LETTERS
- The Hypoxia-Associated Factor Switches Cells from HIF-1 - to HIF-2 -Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion
- (2011) M. Y. Koh et al. CANCER RESEARCH
- 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway
- (2011) X. Pang et al. CARCINOGENESIS
- VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway
- (2011) Long Yang et al. CELL BIOLOGY INTERNATIONAL
- Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
- (2011) H. Huang et al. CLINICAL CANCER RESEARCH
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
- (2011) Pipsa Saharinen et al. TRENDS IN MOLECULAR MEDICINE
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
- (2010) Young Jun Koh et al. CANCER CELL
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
- (2010) S.-S. Chae et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
- (2010) K. Staufer et al. CURRENT CANCER DRUG TARGETS
- Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice
- (2010) X. Qu et al. DEVELOPMENT
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
- (2010) Jennifer S. Michaelson et al. mAbs
- A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
- (2010) J. L. Brown et al. MOLECULAR CANCER THERAPEUTICS
- Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
- (2010) A. Coxon et al. MOLECULAR CANCER THERAPEUTICS
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
- (2010) J. E. Bohonowych et al. Journal of Oncology
- Loss of Endothelial Tie1 Receptor Impairs Lymphatic Vessel Development-Brief Report
- (2009) Gabriela D'Amico et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Endothelial deletion of hypoxia-inducible factor-2 (HIF-2 ) alters vascular function and tumor angiogenesis
- (2009) N. Skuli et al. BLOOD
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
- (2009) Patrick Nasarre et al. CANCER RESEARCH
- Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
- (2009) N. Gaspar et al. CANCER RESEARCH
- Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
- (2009) Zaher K. Otrock et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pathways mediating VEGF-independent tumor angiogenesis
- (2009) Napoleone Ferrara CYTOKINE & GROWTH FACTOR REVIEWS
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents
- (2009) Kenneth H. Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Angiopoietin-2 Exocytosis Is Stimulated by Sphingosine-1-Phosphate in Human Blood and Lymphatic Endothelial Cells
- (2008) Cholsoon Jang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
- (2008) Y. Okawa et al. BLOOD
- VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
- (2008) G Thurston et al. BRITISH JOURNAL OF CANCER
- Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells
- (2008) M. Calvani et al. CANCER RESEARCH
- The role of hypoxia-inducible factors in tumorigenesis
- (2008) E B Rankin et al. CELL DEATH AND DIFFERENTIATION
- SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers
- (2008) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Targeting Hsp90: small-molecule inhibitors and their clinical development
- (2008) Tony Taldone et al. CURRENT OPINION IN PHARMACOLOGY
- Dominant-Negative Hsp90 Reduces VEGF-Stimulated Nitric Oxide Release and Migration in Endothelial Cells
- (2007) Robert Q. Miao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PI3K/PTEN signaling in tumorigenesis and angiogenesis
- (2007) Bing-Hua Jiang et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Development and application of Hsp90 inhibitors
- (2007) D SOLIT DRUG DISCOVERY TODAY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More